BCL2L1 and Thrombocytopenia: In preclinical trials with in naturally aged mice, PZ effectively clears senescent cells and rejuvenates tissue stem and progenitor cells without causing severe thrombocytopenia, thus Bcl‐xL PROTACs may be developed as safer and more potent senolytics than Bcl‐xL inhibitors.